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We have previously identified a novel atherosclerosis quantitative trait locus (QTL),
Arch atherosclerosis 5 (Aath5), on mouse chromosome 10 by three-way QTL analyses
between Apoe−/− mice on a DBA/2J, 129S6 and C57BL/6J background. The DBA/2J
haplotype at the Aath5 locus was associated with smaller plaque size. One of the
candidate genes underlying Aath5 was Stabilin-2 (Stab2), which encodes a clearance
receptor for hyaluronan (HA) predominantly expressed in liver sinusoidal endothelial
cells (LSECs). However, the role of Stab2 in atherosclerosis is unknown. A congenic
line of Apoe−/− mice carrying Aath5 covering the Stab2DBA allele on a background
of 129S6 confirmed the small reductions of atherosclerotic plaque development. To
further determine whether Stab2 is an underlying gene for Aath5, we generated
Stab2−/− Apoe−/− mice on a C57BL/6J background. When fed with a Western diet for
8 weeks, Stab2−/− Apoe−/− males developed approximately 30% smaller plaques than
Stab2+/+ Apoe−/− mice. HA was accumulated in circulation but not in major organs in
the Stab2 deficient mice. STAB2-binding molecules that are involved in atherosclerosis,
including acLDL, apoptotic cells, heparin and vWF were not likely the direct cause of the
protection in the Stab2−/− Apoe−/− males. These data indicate that reduction of Stab2 is
protective against atherosclerotic plaque development, and that Stab2 is a contributing
gene underlying Aath5, although its effect is small. To test whether non-synonymous
amino acid changes unique to DBA/2J affect the function of STAB2 protein, we made
HEK293 cell lines expressing STAB2129 or STAB2DBA proteins, as well as STAB2129
proteins carrying each of five DBA-unique replacements that have been predicted to
be deleterious. These mutant cells were capable of internalizing 125 I -HA and DiI-acLDL
similarly to the control cells. These results indicate that the amino acid changes unique
to DBA/2J are not affecting the function of STAB2 protein, and support our previous
observation that the reduced transcription of Stab2 in the liver sinusoid as a consequence
of the insertion of a viral-derived sequence, intracisternal A particle, is the primary
contributor to the athero-protection conferred by the DBA/2J allele.
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INTRODUCTION

showed that the promoter region of Stab2 in the DBA/2J genome
contains a viral-derived sequence, intracisternal A particle (IAP),
and that Stab2 gene expression is lower in the liver sinusoidal
endothelial cells (LSECs) of DBA/2J mice compared to 129 mice,
suggesting that the reduced expression of Stab2 could lead to the
high plasma HA levels in DBA/2J mice (16).
Stab2 is reported to be expressed in the atherosclerotic plaques
in humans, although the role of Stab2 in atherosclerosis is
unclear (17). Knockout mice of Stab2 exhibit more than 10
times higher plasma HA than the wild-type mice, but otherwise
are grossly normal (18). Schledzewski et al. demonstrated that
double knockout mice of Stab1 and Stab2 show glomerulofibrotic
nephropathy due to accumulation of a transforming growth
factor (TGF)-β family member growth differentiation factor 15
(GDF-15) and other ECM material in the blood, while single
knockout mice of Stab2 are normal (18). The double knockout
phenotype also leads to placental deficiencies that substantially
decrease litter numbers not seen in single Stab1 or Stab2 KO mice
(19). Hirose et al. showed that tumor metastasis was prevented
in Stab2 knockout mice (20). However, there is no investigation
directly evaluating that Stab2 is involved in atherosclerosis.
Finally, although the major ligand of STAB2, HA, is implicated
in atherosclerosis, HA could be protective or harmful depending
on the context (21–24).
In this study, we demonstrated that Aath5 affects
atherosclerosis by establishing an Apoe−/− line on a 129S6
background that are homozygous for Aath5 of DBA/2J allele,
and further examined the role of Stab2 in atherosclerosis by
generating Stab2−/− Apoe−/− mice on a C57BL/6J background.

Atherosclerosis, which accounts for more than 30% of all
deaths worldwide, is a complex multifactorial disease (1). Wellknown risk factors of atherosclerosis include hyperlipidemia,
hypertension, diabetes and chronic inflammation, as well as
lifestyle risk factors such as smoking, high calorie/nutritionally
poor diets and lack of physical activity. Many genetic
factors additively or interactively determine susceptibility
to atherosclerosis of an individual, although the genetic factors
involved in the pathogenesis are not fully understood (2, 3).
Mouse models of atherosclerosis with different genetic
backgrounds show clear evidence of genetic factors affecting
susceptibility to plaque development (4, 5). For example,
atherosclerotic plaque size of apolipoprotein E-deficient
(Apoe−/− ) mice on a DBA2/J background (DBA-Apoe−/− ) is
larger than those on a C57BL/6J background (B6-Apoe−/− ) or a
129S6 background (129-Apoe−/− ) (6–8). To identify the genetic
factors influencing the plaque size, we previously performed
quantitative trait locus (QTL) analysis using the F2 population
from DBA-Apoe−/− x 129-Apoe−/− , and identified two new
QTLs, Aath4 on Chromosome (Chr) 2 and Aath5 on Chr
10 (7). Analyses of plaque size in the F2 population revealed
that the DBA allele of Aath4 confers susceptibility for plaque
development in the aortic arch area, whereas the DBA allele
at Aath5 is protective. The atherosclerosis-enhancing effect
of Aath4 likely overrides the protective effect of Aath5, since
DBA/2J strain is more susceptible to atherosclerosis compared to
B6 and 129. We further showed that Mertk is a responsible gene
underlying Aath4 (9).
Aath5 was also detected by a QTL analysis using a cross
between DBA-Apoe−/− and B6-Apoe−/− , while it was not present
in 129-Apoe−/− x B6-Apoe−/− (8, 10). Collectively, these results
indicate that the DBA/2J allele of Aath5 is unique, whereas 129S6
and C57BL/6 alleles share the same sequences. Comparison of
Aath5 haplotypes between DBA/2J, 129S6 and C57BL/6 revealed
that only a few genes in this region exhibit this pattern. Among
those genes, Stabilin2 (Stab2) has potentially harmful amino acid
substitutions, as well as differential mRNA expression levels in
macrophages and aortic tissues (7). Although no SNPs relevant
to atherosclerosis, or notable cis- or trans-expression QTLs were
detected within the interval in the mouse genome, variations near
or within the human STAB2 gene are associated with coronary
restenosis (p = 1.0 × 10−7 ), coronary disease (p = 1.0 × 10−5 )
and stroke (p = 5.4 × 10−4 ). Thus, Stab2 is a potential candidate
for Aath5.
Stab2 encodes a scavenger receptor primarily expressed in
the sinusoidal endothelial cells (SECs) of the liver, spleen,
bone marrow and lymph nodes. Many ligands are known
to bind STAB2, including hyaluronic acid (HA), heparins,
chondroitin sulfates, modified LDLs, collagen, von Willebrand
factor/Factor VIII and advanced glycation end products (11–
15). We previously reported that plasma concentration of HA
is ten-fold higher in DBA/2J mice than in 129S6 and C57BL/6J
mice, and that the difference is linked to the Stab2 locus but not
to the other gene loci involved in HA metabolism, such as HA
synthases, hyaluronidases and other receptors (7). We further
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MATERIALS AND METHODS
Animals
Apoe−/− mice on C57BL/6J and 129S6/SvEvTac backgrounds
were generated in our laboratory as previously described (5).
Mice were fed regular mouse chow (3002909-203, PicoLab) and
handled under protocols approved by the Institutional Animal
Care and Use Committees of the University of North Carolina
at Chapel Hill and the University of Nebraska. Under specific
nutritional protocols, the mice were also fed a Western-type diet
(42% calories from fat, TD88137, Harlan Teklad).

Generation of a Congenic Aath5DBA/DBA
Line on a 129S6 Background
We have established Aath5DBA/DBA congenic mice by
continuously backcrossing Chr 10: 86 Mb (Aath5) of
DBA/2J onto the 129S6 (Taconic Biosciences) background
for ten generations. The DBA allele was discriminated
from the 129 allele by PCR using primers that detect a
fragment length polymorphism within the intron 1 of
Stab2 gene: 5’-CTGAGAAACAGGTGGCATGT-3’ and 5’TATGCCTGCCTGACGGATTA-3’. The 129 allele produces
a 190 bp band while the DBA allele produces a 170 bp band.
A heterozygous mouse at the tenth backcross generation was
then crossed with 129-Apoe−/− mice. Heterozygous mice were
further intercrossed to generate homozygous Aath5DBA/DBA
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Sudan IV. Root lesions were also measured on the captured
images using Image J software.

mice. The extent of the DBA based genome were determined to
be 84.6 Mb to 93.9 Mb using SNP genotyping Mouse Universal
Genotyping Arrays (GigaMUGA) with a help from the UNC
Systems Genetics Core (25). The Aath5DBA/DBA mice were fed
regular chow (3002909-203, PicoLab).

Tail-Vein Injections of 125 I-HA
Mice were injected via the tail vein with 1 mg/kg of 125 I-HA. After
circulation for the indicated times, the mice were euthanized and
tissues were measured for radioactivity and mass. The data is
presented as CPM/mg tissue.

Generation of Stab2−/− Apoe−/− Mice
Stab2−/− mice were generated by CRISPR-Cas9 mediated gene
editing on the C57BL/6J background in the UNC Animal Models
Core. A guide RNA was designed in exon 24 of Stab2 gene
(Figure 1A) originally aiming to generate a mouse line which
carries a single G864D mutation. When a plasmid containing
the guide RNA and Cas9 sequences was co-injected together
with a donor template oligo for homology-directed repair
(HDR) into the pronuclei of the fertilized eggs derived from
C57BL/6J, eight mice were obtained. Sequencing of the target
site identified that seven mice had variable insertion/deletion
mutations. A mouse carrying a mutant allele with one base-pair
deletion (Figure 1A) was chosen as a knockout line and further
mated with B6-Apoe−/− mice to generate Stab2+/− Apoe−/−
mice on the C57BL/6J background. The lack of STAB2 protein
was confirmed by western blotting using a goat polyclonal
antibody against STAB2 (M-20, Santa Cruz). Stab2−/− Apoe−/−
mice were obtained by mating Stab2+/− Apoe−/− parents,
and the littermate Stab2+/+ Apoe−/− mice were used as
controls. Genotyping of Stab2 was performed by PCR using the
following primers: forward primer to detect wild-type allele;
5’-AGCTGTGTCTGCAATGACGG-3’, forward primer to detect
the mutant allele; 5’-AGCTGTGTCTGCAATGATGA-3’ and the
common reverse primer; 5’-GAAGCAGCATGGCAGGTTAT3’. Genotyping of Apoe was performed by quantitative PCR
using the following probe and primer sets: wild-type probe:
5’-TGGGAGCAGGCCCTGAACCG-3’; wild-type forward
primer:
5’-GAGTGGCAAAGCAACCAACC-3’;
wild-type
reverse primer 5’-CAGCGCAGGTAATCCCAGAA-3’; knockout
probe: 5’-ACCCATGGCGATGCCTGCTTGCCG-3’; knockout
forward primer: 5’-GACGGCGAGGATCTCGTCG-3’ and
knockout reverse primer: 5’-TATGTCCTGATAGCGGTCCG-3’.
Because C57BL/6 are relatively resistant to plaque development,
Stab2−/− Apoe−/− mice and Stab2+/+ Apoe−/− were fed a
Western-type diet (42% calories from fat, TD88137, Harlan
Teklad) to accelerate atherosclerosis.

Phagocytosis Assay
Phagocytosis assays using isolated peritoneal exudate cells were
performed as previously described (9). Briefly, three-monthold male mice were intraperitoneally injected with 1 ml of 4%
thioglycollate in 1x PBS. The elicited peritoneal cells were isolated
at 3 days after the injection and incubated in 6-well-plates in
DMEM supplemented with 10% fetal bovine serum at 37◦ C for
an overnight. Apoptosis was induced in human Jurkat T cells
(ATCC) by incubating with 1 µM staurosporine (Sigma) for 3 h.
After staining with 100 ng/ml pHrodoTM Red SE (Thermo Fisher
Scientific) for 30 min at room temperature, the apoptotic cells
were added to the peritoneal cells at 1 × 106 cells per well.
After incubating for 60 min at 37◦ C, cells were detached from the
plates by Accutase (EMD Millipore), stained with anti-CD11bFITC (1:200, Clone M1/70, BD Pharmingen) and 0.5 µM DAPI.
Phagocytosis was measured on LSRFortessa (BD Biosciences)
and assessed by FlowJo software.

Plasma Levels of STAB2 Ligands
Plasma concentrations of HA, heparin and vWF were
measured with Hyaluronan DuoSet ELISA kit (R&D
systems), Unfractionated Heparin ELISA for Rodent Plasma
Samples (Lifespan Technologies) and Mouse vWF ELISA
Kit (LifeSpan BioSciences), respectively, according to the
manufactures’ instructions.

Size of HA
Serum samples of DBA/2J mice were mixed with an equal
volume of 100 mM sodium acetate (pH 6.0) and incubated
with or without 20 U/ml of Hyaluronidase from Streptomyces
hyalurolyticus (EMD Millipore) for 2 h at 60◦ C. Samples were
then incubated with 0.5 µg/µl of protease K for 3 h at 60◦ C,
followed by 10 min at 95◦ C for inactivation of protease K. Nucleic
acids were digested with 10 U/µl Benzonase nuclease (Sigma)
overnight at 37◦ C. The samples were precipitated with ethanol
and separated by electrophoresis on a 2% agarose gel in TAE
buffer. The gel was incubated with 0.005% Stains-All (Sigma) in
30% ethanol overnight and de-stained with 10% ethanol. SelectHA HiLadder and LoLadder (Echelon Biosciences) were used as
molecular markers.

Phenotyping of Mutant Mice
Body weight and plasma levels of lipids and glucose were
determined at the indicated age after fasting for 2 to 4 h.
Mice were anesthetized with an overdose of avertin (2,2,2tribromophenol) and perfused with PBS via the left ventricle
of the heart, followed by perfusion with 4% paraformaldehyde.
Atherosclerotic plaque size at the aortic arch and at the aortic
root was measured as previously described (10). Briefly, aorta
was dissected from the fixed mouse and cleared of fat tissues.
Arch lesions were evaluated on the captured images using Image
J software. We previously demonstrated a strong correlation
between the lesion size measured by this method and the plaque
size measured in the cross-sectional aortas (10). The heart
containing the aortic root area was sectioned and stained with
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Endocytosis of 125 I-HA by LSECs
Mouse liver perfusions and LSEC purification was performed
as previously described in Cabral et al. with the additional step
of depleting Kupffer cells with the use of CD11 magnetic beads
(26). Cells were plated on fibronectin-coated 24-well-plates in
Roswell Park Memorial Institute (RPMI) medium with 5% serum
and incubated for 1.5 h to recover and attach to the plate.
The cells were washed and incubated with 1 mg/mL 125 I-HA
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FIGURE 1 | Stab2−/− Apoe−/− mice develop smaller atherosclerotic plaques. (A) Generation of Stab2−/− Apoe−/− mice on a C57BL/6 background. Donor
sequences carrying two mutations are shown (Top). The guide sequence used in the CRISPR/Cas9 genome editing was underlined (middle). Two mutations were
(Continued)
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FIGURE 1 | introduced compared to WT allele. Extra one base pair deletion in Stab2 gene resulted in a knockout allele of Stab2 (bottom). Complete deficiency of
STAB2 protein was confirmed by Western blot using the whole liver lysates from Stab2+/+ , Stab2+/− and Stab2−/− mice. GAPDH was used as an internal control.
(B) Comparison of plaque size at the aortic arch (left) and root (middle), and percentage of plaque area vs. vessel area at the root (right) between the control
Stab2+/+ Apoe−/− and Stab2−/− Apoe−/− mice at 12 weeks old. Mice were fed with a Western-type diet for 8 weeks. Plaque size (µm2 ) was square root transformed
(sqrt) for statistical analysis. n = 10–16, mean ± s.d., *p < 0.05 vs. Stab2+/+ Apoe−/− . ns, not significant. (C) Plasma lipid and glucose levels in Stab2+/+ Apoe−/−
and Stab2−/− Apoe−/− mice. n = 10–16, mean ± s.d. (D) Representative histological sections of the aortic root area from the control Stab2+/+ Apoe−/− and
Stab2−/− Apoe−/− males at 12 weeks old after fed with a Western-type diet for 2 months. Sections were stained with Sudan IV. Bar = 50 µm.

were washed three times with ice-cold Hanks’ balanced salt
solution (HBSS), lysed in 0.3 mol/L NaOH, and radioactivity and
protein content were determined. The values are expressed as
counts per µg of protein.

for 2 h, washed three times with HBSS and radioactivity was
determined with a gamma counter and total cell lysate protein
was determined by Bradford Assay.

Mouse Stab2 cDNA Isolation

Endocytosis of 125 I-HA by Stab2
Expressing Cells

Total RNA was isolated from the liver of 129S6 and DBA/2J mice
using RNeasy mini kit (Qiagen) and cDNA was synthesized by
SuperScript III (Life Technologies) using random hexamers. The
5’ half (3.8 kb) and 3’ half (4.2 kb) of the Stab2 were amplified
separately by PCR and cloned into pCMV6-AC-IRES-GFP-Puro
vector (OriGene) by the overlap in vivo cloning (27, 28). Briefly,
the amplified fragments have sequences overlapping with the
vector end for 60 bp, and with each other for 300 bp. The mixture
of the fragments and vector was directly transformed into Stellar
Competent Cells (Takara). The isolated plasmids were sequenced
and confirmed to have the full-length cDNAs of Stab2129 and
Stab2DBA . Stab2 cDNAs carrying each amino acid mutation were
made using GeneArt Site-Directed Mutagenesis System (Thermo
Fisher Scientific) according to the manufacturer’s protocol.

Endocytosis of 125 I-HA was performed as described previously
(29). Briefly, at least three clones stably expressing STAB2 were
plated in 24-well-dishes and allowed to grow for 2 days prior
to the experiment. Immediately prior to the experiment, cells
were washed and incubated in endocytosis medium (Dulbecco’s
Modified Eagle’s Medium (DMEM) + 0.05% BSA) at 37◦ C for
1 hour followed by endocytosis medium containing 1 µg/mL
125 I-HA. At each time point, cells were washed 3 times with
ice-cold HBSS, lysed in 0.3 mol/L NaOH, and assessed for
radioactivity with a gamma counter. CPM were normalized to
the receptor expression levels as assessed by Western blot analysis
and expressed as pmol HA per fmol receptor.

Stable Transformants of Stab2 cDNA

Endocytosis of acLDL

Both Stab2129 and Stab2DBA cDNAs were transfected into
HEK293T cells, and cells stably expressing Stab2 cDNA were
cloned by puromycin selection. To establish cell lines which
express similar amounts of the transgene, both 129 and DBA
variants were cloned into a pcDNA5/FRT/V5/6xHis-TOPO
plasmid (Thermo Fisher Scientific) and stable clones were
generated in Flp-In 293 cells (Thermo Fisher Scientific) as
previously described (29).

HEK293T cells were grown in DMEM supplemented with 10%
fetal bovine serum. Stab2 cDNA plasmid was transfected into
HEK293T cells using FuGENE HD (Promega) following the
instructions. Forty-eight h after the transfection, medium was
changed to serum-free phenolphthalein-free DMEM, and DiIlabeled acLDL (Alfa Aesar) was added to the cells at the final
concentration of 50 µg/ml. Cells were incubated at 37◦ C for
30 min, washed with PBS and fixed with 4% PFA at room
temperature for 10 min. Fluorescent images of the DiI-positive
cells were captured by Olympus IX81 microscope (Olympus).
Percentages of the DiI-positive cells were determined by
FACSAria II (BD Biosciences) and assessed by FlowJo software.

Direct HA Binding Assay
Flp-In 293 cells stably expressing STAB2 were lysed in 1x PBS
containing 0.5% NP-40 and protease inhibitor cocktail. The
clarified lysate was combined with 20 µL of a 1:1 slurry of antiV5 and 125 I-HA, and incubated for 2 h under slow rotation. The
resin was washed 4 times with 1x PBS containing 0.1% NP40 and evaluated for radioactivity. STAB2 protein was eluted
from the resin with Laemmli buffer, separated by 5% SDS-PAGE
and evaluated by Western analysis to equilibrate counts per µg
of protein.

In vivo Clearance of acLDL
One µg/g body weight of DiI-labeled acLDL (Alfa Aesar) in
PBS was injected into the anesthetized mice by retro-orbital
injection via the right eyes. At each time point, blood was
collected from the left eyes, and the plasma was transferred
to disposable capillaries with 20 µl capacity (#1-000-0200-32,
Drummond Scientific Company). Images of the capillaries were
captured with automatic exposure times using IX70 fluorescence
microscope (Olympus) and SPOT image capture software (SPOT
Imaging). Since each exposure time is in inverse proportion to
the fluorescence intensity, logarithm of the reciprocal of the
exposure time [log10 (1/time)] was plotted as the indicator of the
fluorescence intensity.

Cell Surface and Total Cellular HA Binding
Assay
The amount of HA binding by the cell surface and the total cell
STAB2 was determined as described previously (30). Briefly, at
least three stable clones expressing STAB2 were incubated on ice
with 1 µg/mL 125 I-HA for 1 h at 4◦ C, with or without 0.055%
(w/v) digitonin which permeabilizes the plasma membrane. Cells
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Statistics

area, mice were fed a Western-type diet starting at 4 weeks
of age and until 12 weeks of age to enhance atherosclerosis.
In males, plaque sizes were smaller in Stab2−/− Apoe−/− mice
than in the control mice at both the arch and root areas,
while female Stab2−/− Apoe−/− mice did not show significant
differences compared to the control mice at either arch or root
area (Figure 1B). Plasma total cholesterol and triglyceride levels
in the Stab2−/− Apoe−/− mice were not significantly different
from the control mice in both males and females (Figure 1C).
Plasma glucose levels were also comparable between the two
groups (Figure 1C). The histological sections of the aortic root
area showed accumulation of Sudan IV-positive foam cells within
the plaques in both Stab2+/+ Apoe−/− and Stab2−/− Apoe−/−
(Figure 1D). These results indicate that the lack of Stab2
contributes to a small protection against atherosclerosis in males.

Comparisons between samples were done by t-test or one-way
analysis of variance (ANOVA) followed by Tukey-Kramer’s HSD
test. P < 0.05 was considered as statistically significant. Data were
analyzed using JMP software version 15.2 (SAS Institute) and
SigmaPlot 11.2 software (Systat).

RESULTS
Aath5DBA Is Slightly Protective Against
Atherosclerotic Plaque Development
Aath5 locus on Chr10 (30-101 Mb) was previously identified as
an atherosclerosis QTL. The DBA/2J allele of Aath5 (Aath5DBA )
was associated with smaller plaques, while 129 allele of
Aath5 (Aath5129 ) was associated with larger plaques (7).
To confirm the effect of Aath5 on plaque development, we
generated a congenic Apoe−/− mouse line with Aath5DBA/DBA
by backcrossing the genomic region of DBA containing a
distal portion of Aath5 (84.6-93.9 Mb) to 129-Apoe−/− for
ten generations (Supplementary Figure 1A). The backcrossed
region of Aath5DBA contains Stab2DBA . As expected, plasma
concentration of HA was more than 10 times higher in
Aath5DBA/DBA Apoe−/− mice than in male and female control
Aath5129/129 Apoe−/− mice (Supplementary Figure 1B). Of note,
expression of Stab2DBA was completely suppressed on this 129S6
background because the IAP element interferes with the normal
transcription (16). Plasma cholesterol and triglyceride levels in
the Aath5DBA/DBA Apoe−/− mice were slightly lower compared
to the control mice, although it was not statistically significant
(Supplementary Figure 1C). Plasma glucose levels were
comparable between Aath5DBA/DBA Apoe−/− and the control
mice (Supplementary Figure 1C). Atherosclerotic plaque size
at the arch area was slightly lower in Aath5DBA/DBA Apoe−/−
mice than in control mice in both males and females, although
it was not statistically significant (Supplementary Figure 1D).
At the root area, only female Aath5DBA/DBA Apoe−/− mice
showed significantly smaller plaques compared to the control
mice (Supplementary Figure 1D). These results support that
the backcrossed region of Aath5DBA confers protection against
atherosclerosis. This approach eliminates the potential effects
of genes on chromosomes other than Chr10, although it does
not eliminate a possibility that more than one gene within
the backcrossed region affect atherosclerosis. The effect of
each gene could be either suppressing or enhancing plaque
development. The result nonetheless confirms that gene(s)
within the backcrossed region collectively confers protection and
that there is at least one protective gene within the region. The
effects of genes within Aath5DBA that was not carried into the
genome of Aath5DBA/DBA mice were eliminated.

Reduced Clearance of HA From Circulation
in Stab2−/− Mice
Consistent with previous reports (18, 20), plasma concentration
of HA was elevated by more than 30 times in Stab2−/− Apoe−/−
mice compared to the Stab2+/+ Apoe−/− mice (Figure 2A).
Alcian-blue staining, which detects mucopolysaccharides
including HA, showed positive staining in the root valve
leaflets and the proximal part of the valves (Figure 2B). Despite
the extremely higher plasma HA, the staining pattern in
Stab2−/− Apoe−/− mice was comparable to that in the control
mice (Figure 2B).
When 125 I-HA was injected via tail vein to wild-type mice,
125 I-HA in circulation gradually decreased and dropped to less
than 50% at 20 min (Figure 2C). In contrast, 125 I-HA decreased
for the first 10 min but became stable in Stab2−/− mice. The liver
and the spleen of Stab2−/− mice showed consistently lower levels
of 125 I-HA than those of wild-type mice. Although more 125 I-HA
was accumulated in the kidney of Stab2−/− mice compared to
the wild-type, 125 I-HA decreased to comparable levels as wildtype at 20 min. These results indicate that degradation of HA in
the liver and the spleen was inhibited in Stab2−/− mice and HA
accumulated in circulation. In spite of the high distribution of HA
in the liver and the kidney, less 125 I-HA was detected in the heart
and the lung. The distribution patterns of HA in the heart and
the lung were similar in wild-type and Stab2−/− mice, indicating
these are background levels due to residual blood in the organs
(Figure 2C).
Collectively, these results suggest that clearance of HA from
the liver was reduced in Stab2−/− mice, and that HA accumulated
in circulation rather than in major tissues/organs including
large vessels.

Other Ligands of STAB2
Next we examined whether clearance of STAB2 ligands other
than HA were affected by inhibition of Stab2. Elimination of
apoptotic cells in atherosclerotic plaques plays a critical role
in lesion development. STAB2 recognizes phosphatidylserine
of apoptotic cells and mediates phagocytosis of those cells
(31). We tested the effect of Stab2 deficiency on phagocytosis
using peritoneal exudate cells isolated from Stab2−/− Apoe−/−
and the control Stab2+/+ Apoe−/− mice. When the isolated

Lack of Stab2 Is Protective Against
Atherosclerotic Plaque Development
To test whether Stab2 is a modifier of atherosclerosis, we
generated Stab2−/− Apoe−/− mice on C57BL/6 background
(Figure 1A). Since the C57BL/6 strain is relatively resistant to
plaque development compared to the 129S6 strain at the arch
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FIGURE 2 | Lack of STAB2 leads to the accumulation of HA in circulation but not in major organs. (A) Plasma HA concentrations in Stab2+/+ Apoe−/− and
Stab2−/− Apoe−/− mice (n = 4). Data are mean ± s.d. (B) Alcian blue staining of aortic root area of Stab2+/+ Apoe−/− and Stab2−/− Apoe−/− mice. Arrows indicate
root valve leaflets. Alcian blue-positive mast cells are observed (arrowheads). Bar = 100 µm. (C) Distribution of 125 I-HA in major organs after injection of 1 mg/kg
125
I-HA via tail-vain in Stab2+/+ (WT) and Stab2−/− (KO) mice (n = 3; data are mean ± s.d. *p < 0.05, **p < 0.01, and ***p <0.001 vs. Stab2+/+ mice. ns, not
significant).

result indicates that phagocytosis of apoptotic cells is unlikely
the primary mechanism involved in the athero-protection in
Stab2−/− Apoe−/− mice (Figure 3A).

peritoneal cells were incubated with apoptotic Jurkat cells,
the percentages of macrophages engulfing the apoptotic cells
were not significantly different between the two groups. The
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FIGURE 3 | Lack of STAB2 does not have large effects on its ligands other than HA. (A) Phagocytosis of apoptotic cells by peritoneal exudate cells isolated from
Stab2+/+ Apoe−/− (+/+) and Stab2−/− Apoe−/− (–/–) mice. Apoptotic Jurkat T cells labeled with pHrodo Red were added to the peritoneal cells. After the incubation
for 1 h at 37◦ C, cells engulfing the apoptotic cells were detected by flow cytometry (n = 7-9). Data are mean ± s.d. (B,C) Plasma concentrations of heparin
(B) (n = 10) and vWF (C) (n = 12) in Stab2+/+ Apoe−/− and Stab2−/− Apoe−/− mice. Data are mean ± s.d.

than in 129S6. The heart and the lung also showed low levels
of radioactivity, but no significant differences were observed
between 129S6 and DBA/2J. The low levels of radioactivity are
considered to be background caused by residual blood in the each
organ containing 125 I-HA. These results support that endocytosis
of 125 I-HA in the liver and spleen was significantly decreased
in DBA/2J.
We further isolated LESCs from the livers of 129S6
and DBA/2J and performed endocytosis of 125 I-HA ex vivo.
Consistent with the in vivo results, endocytosis of 125 I-HA by
the LSECs isolated from DBA/2J mice was more than 50% lower
than that of 129 LSECs (Figure 4C). Together, these results
confirm that clearance of HA via LSECs is reduced in the DBA/2J
strain, leading to more than ten times higher concentration of
HA in the plasma of DBA/2J mice. However, since the Stab2
expression in the LSECs of DBA/2J is not completely suppressed,
there is a possibility that the STAB2DBA protein contributes to
further functional defects due to amino acid alterations specific
to DBA/2J.

Heparin, which binds and activates antithrombin, is a ligand
of STAB2 (12). Plasma concentrations of heparin were not
significantly different between the two groups (Figure 3B).
Another ligand of STAB2, von Willebrand Factor (vWF),
mediates vascular inflammation and enhances atherosclerosis by
stimulating the adhesion of platelets onto the vessels (32). Human
GWAS revealed variations of Stab2 gene are associated with
plasma vWF concentration (33). Stab2−/− Apoe−/− mice showed
approximately 1.6 times higher concentration of plasma vWF
compared to Stab2+/+ Apoe−/− mice (Figure 3C). This increase
was statistically significant but small compared to the elevation of
HA, which was 30 times higher in the Stab2 deficient mice.
Taken together, Stab2 ligands other than HA we tested do
not appear to be large effectors of the lack of Stab2 and
do not explain their involvement in the athero-protection
in Stab2−/− Apoe−/− mice.

Reduced Clearance of HA in DBA/2J Mice
We have previously reported that plasma concentration of HA
was over 10 times higher in DBA/2J mice than in 129S6 or
C57BL/6 mice (7). The size of increased HA in the plasma
of DBA/2J mice was approximately 40–100 kDa (Figure 4A).
We have also demonstrated that the expression level of
STAB2 in LSECs of DBA/2J mice (STAB2DBA ) was reduced to
approximately 35% compared to 129S6 or C57BL/6, and that the
promoter region of Stab2 gene in the DBA allele contains a viralderived sequence, IAP, which likely interferes with transcription
of Stab2 (16). To confirm that clearance of HA is disturbed in
DBA/2J mice, we injected 125 I-HA (∼130 kDa average mass) into
129S6 and DBA/2J mice via tail vein, and measured radioactivity
in major organs. At 10 min after the injection, the radioactivity of
125 I-HA was highest in the liver of 129S6, while it was more than
50% lower in that of DBA/2J, suggesting that uptake of 125 I-HA
into the LSECs was reduced in DBA/2J (Figure 4B). The spleen
of 129S6 also showed accumulation of 125 I-HA, although the
radioactivity was approximately 50% of the liver. This reflects that
STAB2 is also expressed in the SECs in the spleen. Similarly to the
liver, the spleen showed significantly lower 125 I-HA in DBA/2J
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Normal Binding and Endocytosis of HA via
STABDBA Protein
Mouse STAB2 protein has a large (2,464 amino acids)
extracellular region composed of multiple conserved domains
indicative of protein-protein interaction. Although no alteration
was found in the HA-binding link domain of STAB2DBA ,
STAB2DBA differs from STAB2129 by 15 amino acid residues,
five of which: R151H, T382S, G864D, P1086L and T1596M,
are potentially deleterious substitutions according to the SIFT
prediction program (7). These amino acids are located in the
EGF-like domains or in FAS domains within the extracellular
region, and could affect polymerization or interaction with other
receptors (Figure 5A). To test the effects of these amino acid
changes on the functions of STAB2, we constructed expression
vectors containing individual Stab2 cDNAs isolated from the
livers of 129S6 and DBA/2J. The vector provides a DDK epitope
tag at the C terminus of the STAB2 protein. A previous report
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FIGURE 4 | Clearance of HA is disturbed in DBA/2J mice. (A) Detection of HA in the plasma of DBA/2J mice. Plasma samples with or without HAase treatment were
separated by 2% agarose gel electrophoresis and stained with Stains-All. (B) Distribution of 125 I-HA at 10 min after the tail-vain injection in129S6 and DBA/2J mice
(n = 3; data are mean ± s.d.). (C) Internalization of 125 I-HA by LSECs isolated from the liver of 129S6 and DBA/2J. LSECs were incubated with medium containing
1 µg/ml 125 I-HA for 2 h, lysed and assessed for radioactivity. The value (counts per min) was normalized to the amount of protein. The experiment was replicated four
times with n = 3 for each experiment. Data are mean ± s.d. **p < 0.01 vs. 129. ns, not significant.

The endocytosis of 125 I-HA by cells overexpressing STAB2129
and STAB2DBA were also comparable (Figure 5F). Moreover,
cells overexpressing STAB2 which carry each of the five
amino-acid mutations did not show significant difference in
endocytosis of 125 I-HA (Figure 5G). Therefore, these amino
acid changes in STAB2DBA are unlikely to contribute to the
high plasma concentration of HA in DBA/2J mice. These data
support our previous finding that the reduced expression at the
transcriptional level of Stab2 in LSECs is the primary contributor
to the elevation of plasma HA.

by Harris et al. had shown that the C-terminal tag does not
affect the expression and function of STAB2 (34). When the
same amount of cDNA was overexpressed in human embryonic
kidney 293T (HEK293T) cells, comparable amounts of STAB2129
and STAB2DBA proteins were detected by Western blot at
approximately 300 kDa and 175 kDa as expected (Figure 5B).
The protein is localized on the cell surface, indicating that
membrane trafficking of STAB2DBA is not affected by the amino
acid alterations (Figure 5C).
To compare the binding capacity of STAB2129 and
STAB2DBA to HA, Flp-In 293 cells stably expressing each
STAB2129 or STAB2DBA tagged with C-terminal V5 were lysed,
immunoprecipitated with anti-V5 resin, and incubated with
125 I-HA. When normalized to the amount of protein levels,
binding of HA to the immunoprecipitated STAB2DBA was not
significantly different from STAB2129 (Figure 5D). To further
examine HA binding to STAB2129 and STAB2DBA in live cells,
STAB2-expressing HEK293T cells were incubated with 125 IHA on ice with or without 0.055% digitonin. Since digitonin
permeabilizes the cells and allows 125 I-HA access to intracellular
pools of STAB2, HA binding in the intracellular compartments
as well as on the cell surface can be detected, which is defined as
total 125 I-HA binding. Despite that each cell line expresses varied
amounts of STAB2, the percentage of 125 I-HA bound to the cell
surface was 18.4 ± 1.4% compared to internal binding of 81.6
± 1.4% in STAB2129 cells. In STAB2DBA cells, the cell surface
binding was 16.1 ± 2.2% while internal binding was 83.9 ± 2.2%.
Thus, there is no significant difference in the trafficking of the
receptor and HA-binding activity in STAB2129 and STAB2DBA
expressing cells (Figure 5E).
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Clearance of acLDL Is Not Affected in
DBA/2J
Since modified LDL, another ligand of STAB2 (35), is known
to enhance atherosclerotic plaque development, we examined
whether the allelic differences of Stab2 influence clearance of
acetylated low-density lipoprotein (acLDL). When incubated
with culture medium containing DiI-labeled acLDL, cells
expressing STAB2129 showed increased uptake of DiI-acLDL
compared to the control cells transfected with the empty vector,
indicating that the cDNA produces functional STAB2 proteins
(Figure 6A). Uptake of acLDL by STAB2DBA was not significantly
different from that by STAB2129 (Figures 6A,B).
To examine the effects of the allelic differences of Stab2
on the clearance of acLDL in vivo, DiI-labeled acLDL was
intravenously injected to 129S6 and DBA/2J mice and its
clearance from the circulation was detected by measuring
fluorescence intensity of the plasma. The injected acLDL was
rapidly cleared in 129S6 mice (Figure 6C). Despite the reduced
amount of STAB2 in the LSECs, DBA mice did not show

9

March 2022 | Volume 9 | Article 818662

Kayashima et al.

Stab2 Affects Atherosclerosis

FIGURE 5 | Amino acid changes in STAB2DBA do not affect internalization of HA. (A) Domain structure of mouse STAB2. Arrowhead indicates the cleavage site that
produces the short form of STAB2. Amino acid (AA) replacements in DBA/2J that were predicted by SIFT program to affect the protein function are shown as [AA in
(Continued)
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FIGURE 5 | 129]-position-[AA in DBA]. Positions of other AA changes predicted to be benign are indicated as *. (B) Expression of STAB2 in the HEK293T cells
transfected with the control empty pCMV6-AC-IRES-GFP-Puro vector (EV) or vectors containing Stab2129 or Stab2DBA cDNA. Cells were lysed at 48 h after the
transfection and analyzed by western blot using antibodies against STAB2 and the DDK-tag. UT: untransfected HEK293T cells. (C) Immunostaining of STAB2 protein
(magenta) transiently overexpressed in HEK293T cells detected by anti-DDK antibody. Nuclei were visualized by DAPI staining. (D) Binding of 125 I-HA by STAB2129
(129) and STAB2DBA (DBA). Lysates of Flp-In HEK293 cells which express STAB2 tagged with V5 epitope were immunoprecipitated with anti-V5 resin and incubated
with 2 µg/ml 125 I-HA. The radioactivity bound to the anti-V5 resin was measured. The value was normalized to the amount of STAB2 protein. At least three clones were
used for each strain. Data are mean ± s.d. (E) Distribution of 125 I-HA bound to STAB2129 and STAB2DBA on the cell surface and in the intracellular compartments.
STAB2-expressing HEK293T cells were incubated with 125 I-HA on ice without (Surface) or with (Total) digitonin, which permeabilize the cells and allow 125 I-HA access
to intracellular pools of STAB2. Cells were lysed and the radioactivity was assessed. Internal binding (%) was calculated as [100 - Surface binding (%)]. Four clones of
129 and three clones of DBA were used. At least four experiments were done for each clone and the values were averaged. Data are mean ± s.d. (F) Internalization of
125
I-HA by STAB2129 and STAB2DBA . STAB2-expressing HEK293T cells were incubated with medium containing 1 µg/ml 125 I-HA for the indicated times, lysed and
assessed for radioactivity. The value was normalized to the amount of STAB2 protein determined by Western blotting. Four clones of 129 and three clones of DBA
were used. Experiments were repeated five times and average values are shown. Data are mean ± s.d. (G) Internalization of 125 I-HA by STAB2 proteins carrying each
DBA2/J-specific amino acid change (P1086L, R151H, T1596M, T382S and G864D) or a mutant STAB2 protein where N-terminus region (1-927 AA) of STAB2129 was
changed to that of DBA2/J (5-mut). STAB2-expressing HEK293T cells were incubated with medium containing 1 µg/ml 125 I-HA for 4 h and endocytosis of 125 I-HA
were assessed as in (F). n = 4. Experiments were repeated five times and average values are shown. Data are mean ± s.d. ***p < 0.001 vs. 129. ns, not significant.

FIGURE 6 | Amino acid changes in STAB2DBA do not affect internalization of acLDL. (A) Endocytosis of DiI-acLDL by the STAB2-expressing HEK293T cells. Cells
were incubated with 50 µg/ml DiI-acLDL at 37◦ C for 30 min. Images were captured after washing with PBS and fixation with 4% PFA. The inserts show the punctate
pattern of intracellular distribution. (B) Percentage of DiI-acLDL positive cells. STAB2-expressing HEK293T cells were incubated with 50 µg/ml DiI-acLDL at 37◦ C for
15 min and analyzed by flow cytometry. Data are mean ± s.d. The *** symbol indicates the value p < 0.001. ns, not significant. (C) Clearance of DiI-acLDL in vivo.
129S6 and DBA/2J mice were intravenously injected with 1 µg/g body weight of DiI-acLDL. Blood was collected at the indicated time points and fluorescence
intensity in the plasma was determined (n = 4 for each strain). (D) Fluorescent images of the liver from the 129S6 and DBA/2J mice 9 min after the injection of
DiI-acLDL. DiI-acLDL particles were distributed along the liver sinusoids similarly in both strains. CV; central vein.

acLDL in vivo, probably because the uptake of acLDL is also
mediated by other scavenger receptors, including SR-A, SR-B
and STAB1.
Taken together, our data suggest that the increased plasma of
mid-sized HA is the major reason that Stab2 deficiency leads to
small protection from atherosclerotic plaque development.

any noticeable delay in the clearance of acLDL (Figure 6C).
At 9 min post-injection, the DiI-acLDL was distributed along
the sinusoids in the liver, and the distribution patterns and
intensities of the DiI-acLDL were not significantly different
between 129S6 and DBA/2J (Figure 6D). The reduced STAB2
expression in DBA/2J does not appear to affect the clearance of
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DISCUSSION

D-glucuronic acid and N-acetyl-D-glucosamine residues.
According to the molecular weight, HA is classified into oligo
HA (o-HA, <10 kDa), low to medium molecular weight HA
(LMW- to MMW-HA, 10–1,000 kDa) and high molecular weight
HA (HMW-HA, >1,000 kDa) (37, 38). HMW-HA can provide
increased viscoelasticity to tissue fluids such as vitreous humor
and synovial fluid (39). HMW-HA is also important in the
cellular microenvironments, modulating cell mobility, immune
cell differentiation, adhesion and activation (40). The breakdown
of HMW-HA, catalyzed by hyaluronidase activity in tissues,
initiates turnover of HA, which enters the lymphatic system and
is further degraded in lymph nodes (41). The degraded HA in
circulation is endocytosed by LSECs, and is degraded to very
short oligos and monosaccharides (42).
Several studies indicate that HA is anti-atherogenic. In a cell
culture system, HMW-HA (average ∼4,000 kDa) significantly
inhibited smooth muscle cell (SMC) migration induced by
platelet-derived growth factor-BB (PDGF-BB) (43). In vivo
experiments also showed that pharmacological inhibition of
HA synthesis by 4-methylumbelliferone (4-MU) accelerated
plaque development in Apoe−/− mice and increased macrophage
recruitment to the plaque (21). Furthermore, daily subcutaneous
administration of HMW-HA significantly reduced the intimamedia ratio and intimal macrophage content after balloon injury
of the common carotid artery in cholesterol-fed rabbits (22). A
recent study also demonstrated that injection of nanoparticles
that are aggregates of HA stabilized plaques in Apoe−/− mice
(44). These results collectively suggest that HA in circulation
is anti-atherogenic.
On the other hand, in atherosclerosis, HA is an abundant
component of plaque matrix (45). Expression of HA synthases as
well as hyaluronidases increase in plaque during inflammation,
and accumulation of fragmented HA in the plaque matrix
stimulates inflammation (46, 47). Inhibition of HA synthesis
by 4-MU reduced neointimal hyperplasia in femoral arteries
of mice after injury (23). The authors reported that, through
binding to the active form of CD44 or other receptors, LMWHA mediates leukocyte adhesion and extravasation, as well as
SMC migration and proliferation following vascular injury (23).
In addition, SMC-specific overproduction of HA promoted the
development of aortic atherosclerosis in Apoe−/− mice (24).
Expression of HA synthase 2 (HAS2) in medial SMC-promoted
SMC proliferation and migration (23). Moreover, HA synthase 3
(HAS3) knockout mice developed smaller atherosclerotic plaques
(47). These results suggest that HA in the plaque ECM could
be pro-atherogenic.
The contradictory results could be due to the size of HA,
location of HA accumulation and the stages of atherosclerosis.
There is also a potential contamination of endotoxin or other
bioactive molecules in animal-derived HA for in vitro work,
which could affect proper evaluation of the HA-intrinsic effects
(48). In our analysis, the size of accumulated HA in the plasma
of DBA/2J was estimated at approximately 40–100 kDa, which
is comparable to that of 129S6 mice. Despite the extremely
high concentration of HA in plasma, accumulation of HA in
tissues including the aortic wall was not apparent in DBA/2J and
Stab2−/− mice, suggesting that the effects of STAB2 inhibition

Our previous QTL analyses revealed two major QTLs, Aath4
on Chr 2 and Aath5 on Chr 10, where the DBA allele of
Aath4 confers susceptibility to atherosclerosis, whereas, DBA of
Aath5 is protective (7, 8). DBA/2J strain is more susceptible
to atherosclerosis compared to C57BL/6 and 129S6, since the
protective effect of Aath5 is not large enough to overcome
the effect of Aath4. Still, dissecting those factors is a necessary
step to better understand the whole genetic structure of a
common disease like atherosclerosis that consists of many little
factors. Our study using the backcrossed mice and the geneedited mice demonstrated that Stab2, a candidate of Aath5, is
likely a modifier of atherosclerosis, but the effect can be easily
flipped depending on the genotypes of other loci with greater
influential effects.
While both male and female Aath5DBA/DBA Apoe−/− mice
tend to show smaller plaques, only male Stab2−/− Apoe−/−
mice showed statistically significant protection. The malespecific phenotype of Stab2−/− Apoe−/− mice is consistent
with our previous observation that Aath5 was detected in F2
males of the DBA/2J x 129S6 cross (7). Although there is
no direct evidence that explains the male-only phenotype in
the Stab2−/− Apoe−/− , many sex-dependent factors, such as
sex hormones, are known to influence atherosclerosis, vessel
diameter and blood pressure (36). Female Stab2−/− Apoe−/−
could be protected by the combination of these factors. The
phenotype in Aath5DBA/DBA Apoe−/− mice could be affected by
other gene(s) which also underlie Aath5. The background of
Aath5DBA/DBA Apoe−/− mice is 129S6, while Stab2−/− Apoe−/−
mice are on a C57BL/6 background, which might have
introduced the difference as well. Furthermore, although
our original QTL analyses found the athero-protection was
restricted at the aortic arch area and not at the aortic root
(7, 8), the protection was not strictly limited to the aortic
arch in the congenic Aath5DBA/DBA Apoe−/− (129S6) and in
Stab2−/− Apoe−/− (C57BL/6) mice. This suggests a possibility
that the many other loci are influencing to the atherogenesis at
the aortic root area more than in aortic arch area, limiting the
ability to detect small effects by the QTL analyses.
In the current work we explored several possible mechanisms
by which the lack of Stab2 could lead to the protection
against atherosclerosis. In humans, there is a report that
Stab2 is expressed in atherosclerotic plaques, although the
function of Stab2 is unclear (17). Our previous microarray
experiments showed that the expression of Stab2 in macrophages
was almost undetectable in mice (7). Furthermore, our data
presented here show that phagocytosis of apoptotic cells was
comparable between macrophages isolated from the wild-type
and Stab2−/− Apoe−/− mice (Figure 3A). Our data, thus suggest
that the influence of Stab2 on the phagocytosis of apoptotic cells
by macrophages in atherosclerotic plaques is negligible.
The major ligand of STAB2 is HA, and consistent with
previous reports (18, 20), plasma HA concentration was
more than 30 times higher in Stab2−/− Apoe−/− mice than
in the control Stab2+/+ Apoe−/− mice (Figure 2A). HA is
an unbranched polysaccharide consisting of alternating
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phenotypes due to animal-to-animal variations. Nevertheless, we
point out that all four independent sets of crosses (two previous
QTL analyses and current congenic as well as Stab2−/− Apoe−/−
mice) showed small but significant protective effects of the
reduced STAB2 protein. In no case did we observe significant
effects in an opposite direction. Further studies are necessary to
determine if the direct effector(s) among the many ligands of
STAB2, other than HA, affect plaque formation.

on the SMC-derived HA within the plaque are considered to
be small.
HA is not the only ligand for STAB2-mediated clearance.
Over twenty ligands including HA have been reported, although
unlike HA, many of them are also cleared by other receptors
(49). For example, modified LDLs (oxLDL, acLDL) are cleared
by macrophages via several receptors such as CD36, SR-A and
SR-B (50). Plasma lipid levels of Stab2−/− Apoe−/− mice were
comparable to the control mice, indicating that clearance of
modified LDL is unlikely the underlying mechanism. In addition
to HA, chondroitin sulfate also constitutes endothelial glycocalyx
and could be anti-atherogenic (51). Chondroitin sulfate competes
with HA binding on STAB2, although it could be cleared via other
scavenger receptors including STAB1 (13).
Von Willebrand factor (vWF) and Factor VIII (FVIII) also
bind to STAB2. Genetic associations of Stab2 and vWF and
FVIII were suggested by several genome wide association studies
(GWAS). A recent report has demonstrated that vWF binds to
STAB2 protein and is cleared by LSECs in humans (15). The
GWAS Catalog lists significant association of SNPs in or near
the STAB2 gene with circulating vWF and FVIII levels, and
recent human and mouse studies indicate Stab2 is involved in
venous thromboembolism (33, 52, 53). Increased plasma levels of
vWF and FVIII have been shown to enhance platelet recruitment
to endothelial cells (32). Since platelet-endothelial interaction
is a contributing factor in atherosclerosis, STAB2 could affect
lesion development via vWF/FVIII. Although direct binding of
mouse vWF and mouse STAB2 was not observed, STAB2 might
affect stability of vWF/FVIII indirectly via the accumulation of
heparin, which binds to and inhibits vWF, since heparin also
binds STAB2 (12). Our result shows that plasma vWF levels were
1.6 times higher in Stab2−/− Apoe−/− mice than in the control
mice. Although the elevation of vWF was not as dramatic as
HA, which was more than 30 times higher, the accumulation
of vWF could somewhat enhance atherosclerosis reducing the
athero-protective effects by other ligands in Stab2−/− Apoe−/−
mice. Being a large molecule with multiple domains for proteinprotein interactions, STAB2 could interact with other clearance
receptors for various glycosylated molecules (15). We also note
that CLEC4M and SCARA5 are also clearance receptors for
FVIII and their interactions with STAB2 are not known at this
time (54, 55). These mechanisms need to be addressed in a
future study.
Our data demonstrated that DBA-specific amino acid
replacements on STAB2, despite being predicted to be potentially
harmful replacements, did not alter the internalization of HA.
The result is consistent with the fact that all five non-synonymous
mutations are outside of the HA-binding link domain that
controls internalization of HA. The result instead strongly
supports our previous suggestion that reduced transcription
of Stab2 is the primary cause of dysfunction of STAB2 in
DBA (16).
In summary, our results indicate that Stab2 is likely a modifier
gene of atherosclerosis. The protective effects we observed were
small, and probably affected by other factors. Additionally, there
are technical limitations in detecting minor differences in the
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